Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 36
- Registration Number
- NCT01668069
- Locations
- 🇺🇸
Naval Medical Center, San Diego, San Diego, California, United States
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
- Conditions
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2013-11-07
- Target Recruit Count
- 40
- Registration Number
- NCT01640340
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 494
- Registration Number
- NCT01636947
Randomized Double Blind Placebo Control Study in Patients with Schizophrenia
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Pakistan Institute of Living and Learning
- Target Recruit Count
- 303
- Registration Number
- NCT01602029
- Locations
- 🇵🇰
Dow university of Health Sciences, Karachi, Sind, Pakistan
🇵🇰Karwan e hayat, Karachi, Pakistan
🇵🇰Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1015
- Registration Number
- NCT01594749
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01572012
- Locations
- 🇺🇸
Icon Development Solutions, San Antonio, Texas, United States
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 133
- Registration Number
- NCT01549652
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy
- Conditions
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 340
- Registration Number
- NCT01543945
- Locations
- 🇹🇭
Anesthesiology Department, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 338
- Registration Number
- NCT01536691
- Locations
- 🇰🇷
Hyo Jung Kim, Anyang, Gyeonggi-do, Korea, Republic of
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT01536392
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon B. Johnson General Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.